EDIT - Earnings call transcript Q4 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, good morning, and welcome to Editas Medicine Fourth Quarter and Full Year 2020 Conference Call. All participants are now in a listen-only mode. There will be a question-and-answer session at the end of this call. Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Ron Moldaver, Investor Relations at Editas Medicine.

Ron Moldaver

operator. you, Thank and year everyone, our quarter fourth Good conference welcome call. full XXXX and morning, to Earlier we fourth results and year this our corporate providing morning, XXXX. updates issued a for the quarter full release and press financial replay the section on hours its of be two Investors completion. approximately of today's website A will after available call our After remarks, will the open we prepared our call Q&A. for

purposes most may future forward-looking various result quarterly XX-Q, Form during is those of provisions indicated Private this the discussed report from Actual the company's make on statements Harbor remarks differ constitute call factors, results which prospects we the SEC. expectations, file important the these that reminder, our including those materially and under Factors a forward-looking recent a various Securities Risk As Act plans, in Safe Litigation on statements of as the with for of about the Reform by of XXXX. section

statements only Except obligation as representing or law, represent of forward-looking update date. our subsequent In as if any addition, specifically views even disclaim any our we our statements, views upon revise today, any as and required not relied views to forward-looking as be should change. any of by

the our Jim Mullen. Now call over I Chief will turn to Executive Officer,

Jim Mullen

earnings Editas like thrilled start am our several everyone I today you, the Good of Michaels, Editas and Medical with members Chief are With Michelle the Chief I and Lisa morning, this thank everyone call CEO. by me off to you Robertson, our Team, Officer; Thank morning Ron. new as today. how saying Officer. for first to Financial joining speak would us on Executive including

and common the because the editing the since I've Chairman is The to received remarkable Editas why than was drawn technology reason most already this once of many the Since earlier what potentially thought that curing now? was CEO other company diseases month, promise this be assuming originally of of know, were do you uncurable. this As the means of of gene role for I to question been Board I've XXXX.

years, this I started Editas commercialization. enthusiasm as place to that than was And fantastic. related downstream quickly company clinical, company transitions to each people the stage forward preclinical XXXX, growth of The from incredible development of to strategically to continues is foundation strategically sure the as is and company. that grew Over patients. step technology positioned stages. of Biogen that at the CEO these maximize as to company is all for my the were of Is editing this and is through to Editas to The we phase make leading to these along at is opportunity. with the at in working last technology need chance I company in The directly in the and technologies, each smaller advance company capabilities is the of medicines bring success Editas and the three to Biogen itself. When today. an the the components company look

XXXX, global working as all that to XXXX, and but that, of during medicine vivo else our just first But everyone opposed like XXXX the the leader editing had in bring well. we do clinic. did to to before I'd in gene enter world the vivo discuss do the acknowledge hard COVID in, has the all as Now like to ex now of work I'd as associates to I through

with Michaels, and year were ever the cell begin the our and began made medicine with joined for and of of Lisa EDIT-XXX rights momentum pleased me for The cash EDIT-XXX preclinical well manufacturing vivo half and executive Board approval let's with milestones value by at and appointments We an Catalent, operating accomplishments gene puts ocular in today. Azzur cash call We into on Editas manufacturing year-end capabilities agreement patient enabling advancing rate accomplishments of We we of of the with in and the some year, Editas one first million trial good expanded approximately IND initiating our number edited the ago data control transitioned the past programs LCAXX. Editas So of XXXX. these we more million a run the And RUBY enrollment lastly, to in earlier presented $XXX Chatterjee to the this with leadership year, FDA of of the in disease, clinical $XXX XXXX. Meeta of us over by AbbVie file received extended outstanding through fund granted history second EDIT-XXX added net our for potential through clinical new I'm of year. very sickle position our of Lisa to and the operations with a and IND contracts, demonstrating we clinical creating and have raised Officer, trial. the the best-in-class to than as in Medical Chief full proceeds relationships achieve in Directors. to

the in are first EDIT-XXX. X. XXXX already we've patient continue for to pleased Our Cohort key dosing announce trial I'm in goals BRILLIANCE for to the dosed first, patients

Bristol-Myers the cell the clinical to later with data collaboration X/X treatment we treatment We declaring advance an to to beta-thalassemia. the we before finally, and development of is Squibb by RPX, EDIT-XXX cancers We EDIT-XXX file of alpha-beta NK initial engineered for We'll the candidate application also cell tumor T preclinical the expect treatment medical advance ocular IND to which our our medicines. this year. solid at iPSC-derived the trial, our progress year. trial EDIT-XXX of from of want Phase present sickle for continue X/X data BRILLIANCE of dosing of And the the development new initiate a end meetings programs clinical disease. for for retinitis will company's pigmentosa, share the for Phase plan the And medicines cell RUBY trial in

over Chief call herself, to Lisa? Michaels, clinical Lisa discuss to Medical the turn me let and and EDIT-XXX pipeline. EDIT-XXX broader new our our trials Officer introduce review to Now,

Lisa Michaels

finding Thank curative of for I research genetic for you have gene potential diseases most with involved solutions of development both who and across very focused drug for and I'm group the was Bayer Clinical And which our have constitutes in our than treatments joined Editas’ with the update medicine of excited goal where future these industry of I the I'll drive gene first excited in area. Development more pipeline, recent of and I'm care. standard therapeutic XX my premier editing years. to transformative and Editas I interest Thank have dedicated was bone opportunity My disorders you for of for therapy vivo you and marrow Jim. the cell trial an the edited debilitating bringing of the to platform. call with treatments on thank clinical about lead immunology, you, clinical with potentially joined to the and of from with rare onto of into transforming on all Head approval therapeutic creating position, professionals I'm rare are academia begin being introduction pillar gene from the strategy. pleased career, clinic causes patients Pharmaceuticals, both experienced Editas blood by the I development today's the been a resulting us during extremely and pediatric of your spectrum and today. treatment and And diseases very as was to such, hematologist/oncologist. academic my practice on early diseases, in malignancies. training and my to

As last Jim editing in were an the trial. mentioned, to gene the product BRILLIANCE patients in first year, dosed receive ever vivo

demonstrate results blindness, in usually patients we safety Morgan limiting genetic events development of first At were in no Phase conference, a Leber JP recent X/X shared a that for Amaurosis study treated. dose important is of Congenital EDIT-XXX XX that adverse is treatment goal in or cure were this of this program the LCAXX. of the childhood. very retinal Now, that disease, there Type The the finding to the two the

As cohort. to result, us dose next plan the allowed a escalate has to

allow the than light the that feedback this patients expected just sentinel to criteria change allowed is momentum. Additionally, investigators the and will facilitate to help our safety study modify to the from observed visual better us acuity inclusion And is perception. with to regain enrollment, enrollment

As such, the report pleased in first that to we're we dosed patient have adult cohort. the mid-dose

for effects of We continue for the concurrently the the all every of to first primary patients months the EDITs. three and year collect endpoint confirm beneficial follow expected to data safety the treated

end We by data of the expect from share to this trial BRILLIANCE the year. clinical

retinal inherited on of as the uses childhood Syndrome a vivo the disease editing Now ocular progressive following in delivery machinery program in XA. Usher USHXA results on later XXX, EDIT-XXX treatment as follows of vision program of for life. is work different same much our our EDIT-XXX. and in EDIT-XXX that system This in or EDIT-XXX next loss is

reported of are AbbVie we we forward. materials CDMO progressing EDIT-XXX of from our recent meeting, we program also the As transfer manufacturing JP have completed at and Morgan to the

Type candidate program of RPX. a ocular calls the Retinitis Consequently, found are program we've RPX the X third more target on and replace we Our version made to is aimed our is a the blindness, and a strengths to development complex exploiting of throughout gene by or mutations progressive year-end. Autosomal progress gene. as with approach Dominant abnormal at editing are wild-type identify plan Pigmentosa this another excellent

to blindness to to all a significant curative looking groups. to leverage plan we or the treatments in and gene to globe. further potential to the pipeline inherited of other targeting aim across aim for vivo address pre-dispositions future, expand our programs And blindness solve around age Our editing causes need the

ex our second of programs, So vivo focus. transitioning is edited our area now gene medicine to which

program disease for beta-thalassemia. best-in-class, ex medicine Our cell this is sickle is most medicine cell durable a vivo advanced cell autologous EDIT-XXX, potentially and

our study sickle the the expect of Phase enroll first later we patient cell With start the disease, approving to X/X year. RUBY in this FDA

Off cell goal the and December in by the Conference year-end. beta-thalassemia, Editas from And should sickle detected. showed in greater of will successful favor or hemoglobin. and that was we large addition, switching Predictive manufacturing for development sickle Hematology the production the CDXX will affect clinical patients part from to of be the not cell scale that the IND dependent a of we edited clinical using program. treatment editing durable recent Society derived within American were at of and a healthy red with provide the from expected was system and fetal used sickle Preclinical cells was patients disease meeting effects the will with forward presentation cell lives data transfusion In of of EDIT-XXX hemoglobin file donors target Ultimately, into XX% in processing ASH EDIT-XXX EDIT-XXX to than benefit, be cells moving specific. cells and of as in with same presented the XXX the of the of patients disease with that patient EDIT-XXX this that transform demonstrated differentiated potential our believe the beta-thalassemia. efficient

tumor believe of which medicines. the major our to characterized, program next more superior cell HD end solid of killing data of other derived which a have gene for of and iPSC the and Graft year, model than in NK order as toxicities non-clinical the iNK cells meeting that fully At Moving support the as NK at as avoid we with focus cells therapeutic a control benefits on versus directly of out hope NK cell treatment iNK the variety development program, programs. we cells, decided for healthy double potentially the tumor also resources studies other associated last such iNK ASH disease the December's shared a tumor is showing and derived discontinue mimicking of the shelf cytokine completed the we edited from microenvironment, which NK oncology, our treatment edited donor a types. of use were last targeting TGF-beta release iPSC CISH Editas off cells, mark vivo relevant in effective program on iNK syndrome. to cells, these to focus The Host our our learnings tumors. advancing homogeneous, the in medicines By to are cell have potential EDIT-XXX, immunotherapy to in data

along providing is partnership program our milestone alpha-beta an recently and the both Editas resulting with Squibb. program our cell validation expertise. collaboration Overall, across a progress in generated complemented part T gene Our of for editing we've from our and vivo for made payment This vivo medicines technology Bristol-Myers Officer, serious diseases, ex now, iNK important by developing in to progress on provide the people to updates of would living medicines way. like goals Financial building we And Chief look our with I Robertson. momentum and and Michelle to our differentiated, advanced our turn have for editing the over transformational XXXX, our will call forward

Michelle Robertson

Thank a strong good everyone. and Editas remains as you, we financial Lisa, our portfolio advance morning, in position forward.

in in Jim recent last positioned proceeds strengthening substantially ex vivo vivo our Combined the capital the resulted manufacturing financing raised of and the trial, clinical net continued our are As RUBY and with supporting execution, of enabling well mentioned, $XXX and and we year, BRILLIANCE balance of approximately advancement from the our preclinical clinical sheet. million, objectives also candidates. for

extends net XX, compared which This raised were equivalents XXXX. December does cash cash of marketable cash, well approximately million XXXX. this of the in Our earlier December $XXX $XXX million XX our year, include into and as securities not runway as proceeds to million $XXX

to results for million issued million revenue the press from received our release for attributed with agreements. $XX have termination fourth and Revenue earlier and last from in alliance revenue today. $XX of year we increase to expenses, mostly summarized Allergan was period financial well quarter compared XXXX This turning Now to collaborations that the which was of our as previously the full in revenue out-licensing also the other year. as was million deferred and $XX our same

million pipeline as expenses costs well in related to charges driven million the flat advances $XXX in was our ramp $XX payment related growth compared primarily maturing non-recurring EDIT-XXX, spending our and up expenses clinical up XXXX in for by and success and licensors. These were and for to increase G&A with combined as EDIT-XXX remain expanding expenses and our primary our While This year million. collaborations platform drivers our at R&D XXXX, manufacturing XXXX. XXXX our relatively were the million $XX of to full $XX in in to and

XXXX. primary We expect of drivers that in growth these will spending continue to be the

to grew and the the we At employees don't XXX time, will XXX to for from that, BRILLIANCE RUBY these by COVID-XX, Over and organization hand course expect year, Lisa it negative impact in as fact part any over to approximately our material are alluded to excited life-changing of patients. solutions of of we size employees potentially this XXXX. of XX%, increasing our I trials are both be the the of financial with progressing back full-time we Jim. at And end

Jim Mullen

you, our in proud us solidified The company to incredibly commitment and global we the achieved year. global and Thank gene of of editing as vivo, and what hard to amidst these leave the Michelle. leader position were over our last partners. a is poised have pandemic is unwavering work testament achieved in These employees a expand a clinical That accomplishments pipeline. our accomplishments

Operator? capabilities Over progress serve both We has diseases the ultimate momentum to I'm excited and with of the and potentially especially your look the CEO. patients' humbled we differentiated in the I've and up permanent to forward XXXX the change serious last them the call Q&A. this towards range will goal it medicines that the weeks, diseases. patients We last three suffering these about and all transformative of for years developing amount our three And interest support. lives. open will a Editas to thank a as over trying Editas to cure, that, of across you continued for and tremendous is generate from learned company

Operator

Barclays. Instructions] Wang Thank first with comes question you. And from our [Operator Gina

Your question, please.

Unidentified Analyst

our I for if on have taking thanks I Hi, this is may. question. Sheldon Gina, for two

how and how you implicitly, the could in the second patients cohort expect period So X is much required the remind we And beyond, waiting is EDIT-XXX. on many update year-end? on could and before for first – in us EDIT-XXX, question my

how recent given So Thanks. the Bluebird, overall are thinking the adverse about in by cell approach events and conditioning you regimen sickle reported disease?

Lisa Michaels

these for will All right. Lisa and I questions. it's jump I Michaels, that's guess me, in two

occurs one the weeks to the starting – there what each first think the was after are with waiting is first By period asked, six you four dosed that that two regarding I protocol. So in waiting period. to LCAXX patients protocol

So first able patient let were know very to everybody in the that happy to January. our we're in mid-dose cohort actually actually we back dose

the be that in – the of on period enroll two. periods in safety we back can major safe to sometime no follow-up we in so dosed a be if will would see cohort. have it's before the for waiting patient patient second to And several order first or of the weeks safety That we the coming next we for that then and patient, onto move one time next determine in concerns second the then patient approval have if the

So being in at based patients four timeline the we're looking mid-dose dosed moment. that at the upon cohort

up to have are also first several return also being two follow in in both the patients We planned next of visits for patients visits X, cohort weeks. the scheduled for those

safety continue every those basis, patients three after months efficacy. looking additional the and to follow-up as initial we're mid well on as an safety, for both long-term where We follow

conclusion. move both we're combination, looking, significant combination patients of robust with to dataset and second one we enough so amount give forward safety, And be efficacy we hopefully able with the cohort the have of as to in signs will early of first regarding in some a nice

that's pretty in year more half share we in why to So targeted data. are the order much the second of

to of data set as back of friends in into I suddenly carefully part has as treated, not well substantial and years patients I also as well study, of second that program. several as all of which this they cautiously their number a but For participated amount watching patients a very have in the very moment. feel have Bluebird, only think the very, treatment my and sympathetic who the we're very question, at Bluebird colleagues

therapy much here at patient it's as As similar are really – same watching I very similar clinical think the we're even endpoints, not so interchangeable. to different population, globins program therapy, a gamma a clear a lent laboratory based is important as the approaches. on than doing well an gene those virus endpoint, procedures and lent our as injection gene beta-globins as well patients we're doing and keep are functioning though is to the different overlapping that to gene the and also the distinctly distinctly between what as delivery treating a of also with patients non-viral moment, treat also program the approach a being The basically them in and gene, actually putting and normal very Bluebird is sorry, virus it program, editing. the actually part – They Bluebird approach doing

moment very not we So are that very move the have you any be the they clear at that gene closely potential do encountered from this same into the carefully have a will to program. it's really our forward. and But outcomes moving as approach editing because the we risks watching affect

Unidentified Analyst

Okay. Thank you.

quick maybe period. a on you and period, clarification second the four mentioned waiting six you mentioned a waiting So to the weeks, later then just

four the weeks six to or is of So periods each the them? two one waiting combined

Lisa Michaels

is each treated So sequentially. patient

have to patient the follow-up, one to treat second for have then and we patient, wait we patients. wait the subsequent do follow-up So for ability first,

Unidentified Analyst

thank you so much. Got it,

Lisa Michaels

Yes.

Operator

you. Thank

question next JP from Our Asimov Morgan. Cory is with

Your question please.

Turner Kufe

question. for taking good Thanks morning. Turner for Hey, my is Cory. This on

the assay respect potency it And timelines with are delays? the RUBY how you any that you to prior cause trial those requested efficacy future with so to FDA improved where won't just intersecting portion? do enrolling just see the So, the

Lisa Michaels

is described into just and the a at to for divided understand to basically I similar helpful LCAXX. it's actually – that rule So very a protocol basically least what

were who provide that ensure but us first unquote, times part the are The efficacious. we're observation is patients safe, of quote safety that to able that study patients treated to long enough cohort, in be and couple doing between allows of what actually both also to

clarity move has that we'll assay. the that we allowed planning so year the bit really are actually exactly little they the regarding we timeframe work time kind actually more agency through and a sometime that's us of back questions have plan. of a the as same defined to In had, the So the from the continue forward just this of clearly that go to planned in FDA and to period meantime, mid type potency with

agree parallel not it's something will progress FDA easily already the the done starting. forward. But with It's that work in our hopefully that interfering So can that our be moving to we're with timelines.

Turner Kufe

helpful. that's you. Great, Thank

Lisa Michaels

Okay.

Operator

Thank you.

Our next Company. question from Phil with Cowen Nadeau & is

question Your please.

Phil Nadeau

Good morning, thanks for taking my question.

EDIT-XXX for necessary on the the into a talk and USHXA, it a more First clinic? you program can to is what about get question bit

Lisa Michaels

with candidate in So various effect I of and doing that candidate, more year. that basically non-clinical think clear different later done particular of this to we're forward have are declare that get trying before anyway really space, confirmation we and the to just largely clinical moving we're models hoping is progress what we in

Phil Nadeau

then Got competition, prior around plus data second to it. on of What In on you the approach generally about trial? a into moving what need type that the concerns can forward? will to that to advance the proof and you concept pivotal Bluebird question XXX. bar talk of be see And of the light do maybe the

Lisa Michaels

confused. what see I'm a we clinical with virus trial? or lent Are in we're seeing talking little about what our we

Phil Nadeau

regimen. my so also the preconditioning concern about Well, is think I

about concern is a plus field. regimen, crowded relatively it's preconditioning there So the

So XXX continue pivotal into investment to holding move to in program? can you to that talk about you're a it the the study, bar

Lisa Michaels

In told settings consequence to concerns sequential B-cell during concerns time such related also a to gene were I that versus improvement editing more over proof be talked gene at was improvement is using we about a of going next that physiologic safety these problem of and safety on more I of and which a as, need it hemoglobin the targeting one in even gamma-globulin the BCLXXA, the the a known remind level F. safety and here to theoretical therapy and people particular which looking for changes lent both setting, the as part basically particular locus, theoretical of the mimic at at approach virus targets editing. Morgan, gene clinical each there in we're as after think, people are the point lot JP defined it, such plans I other take as physiologic that a is see sequential I leukemia, prior that time really had place going versus that you of

not of for So use go the I regimen, not to regimen, is with one and the going of course even the people related are that think conditioning the will that of think which concerns to that marrow the potential much whether less or biggest a safety. of busload. I the conditioning. was the are the are looking the have lot programs also and concerns things the with at conditioning autologous all little these is be did cures. Obviously do you're is considered that A lent In as of come always to actually been to advantage with with long-term, agent effects bit program differentiate hurdles with short-term, associated a patients have related the of the up over one of such for transplant, patients to it recently standard what care bone of virus alkylation treating these able because many the

excellent as long-term. outcomes, clinical able I that, think focus also we're main do being still and improve but kind all watching that on think I the So all move but only forward these getting programs waiting safety and to with goal is we not of

Phil Nadeau

very Great. you. Thank helpful. That's

Lisa Michaels

Okay.

Operator

you. Thank

with Matthew comes Morgan question Stanley. next Harrison from Our

Your question please.

Costa Sean

the quick you. everyone. to and Thank Costa on you Hello, this for be are cells program This for steps do for program. to When an A be is the question IND from will NK think Sean what filing? ready you needed us Matthew. ready IND file

Lisa Michaels

jump HD – versus cells, of program forward in fact for using But to for become more a of of I'll we iPSC moving as with actually the the an forward program. began an NK more EDIT-XXX the much edits well the to filing to guess, think advantages the huge with amount familiar type program. NK as cells as we of benefits making began IND NK were human iPSC I and our aware I we're the derived that progress process be doing the shelf we off with much of moving

now, the of right dive we're would first be we're or deep at doing approach study. those to concept best and learnings now looking that clinical for proof that with is our our taking what into a iNK So program candidates what

I probably bit more able timeline for give am So a you IND. targets the clear little well, provide a on think, we'll information I to specific before the

Costa Sean

Great, thank you.

Operator

you. Thank

from Our next question is with Truist Lee Securities. Jon

please. question Your

Miguel Coelho

Hello, in our taking you Miguel for filling for Thank this Jon Lee. is Coelho questions.

will also What to Phase there near how Regarding might is perspective to you. might in restore to near EDIT-XXX, BCVA at vision. you get how sufficient conservative efficacy be influence your year, editing think XX% full X your be normal be the here? results And and Thank can we do close more but estimate vision? predictions according suggest XX% editing normal was done The Optics required Publications

Lisa Michaels

other threshold quality questions think to sorry? I the one I'm for is the edits two is there so there. Okay, related XX% One what, was and

Miguel Coelho

well one patients in in that you they the efficacy this influence lower X, how see before are enroll I basically the how and can other related to readout? is BCVA see treated, trial BCVA, the when so will the Phase read higher The but improvements because will

Lisa Michaels

Okay.

as or can looking is get patients So only some defined also whether We're we what not we're very a a readout would one patients. look gun improvement mind barrel. to be these primary terms looking that open related BCVA several efficacy we’re of at measurements these different in at. of actually at keeping for down

and also visual as did any we're improvements with to Lustrum at the potential can also looking maze. perimeter free, in and be field it of a very we're So use function looking similar at through measured mobility

vision. one real more chance as patients having. a patients to themselves than collecting information provides one a real I each be the that to quality those patients, which our terms these benefits we're think are today, the on as going of across – fall we'll see of I think of improvement And are It in for benefits we're true the potential have of where measure. in may better

provide on why editing. on one opposed be just efficacy robust reason focusing another I'd the just like So of readout to able a amount endpoint. to to these to second patients, more related question the as of To

however, much everybody the be upon to those threshold good for modeling I that you, think versus And tell data, response, can greater you're that the in had our original than XX% two based a coming are frequency be really could trial. response. expecting out vision and editing is still the patients is aware I vision. actually first be XX%. how what lost data where XX% treated – that is considered With XX%. was mid-dose And What to if we optical was we're maintain with only the is chose

Miguel Coelho

you thank much. Excellent, so

Lisa Michaels

Yes, you. thank

Operator

you. Thank

Our next Jay from Oppenheimer. is with Olson question

please. question Your

Jay Olson

questions. any your strategy any Hi, those? the Maybe that in-line capital to direction there can can thank with the on fill how making for delivery to in question and of acquisition I-O your then new And or you in franchises about company? the resources a allocating changes for you. on technology the for, you congrats taking maybe talk across Jim, Thank or talk planning or you make you're about in the maybe platforms? you'd then ocular allocation, gaps are hemoglobinopathy stitching you prioritize that like And leadership, finally, all

Jim Mullen

little from part. Michelle try of Jay, This three on is the of thanks. me get help probably Jim, and those all bit Okay. let a first

because third. investments your the finish also part question, – a vivo me those So that is, doing probably go little each a exactly in into at roughly we well making as – I it's we big second question. it's looking which platform technologies, was three XXXX, platforms the not third, platforms, way we're and and in that allocation, think not let bears iNK and bit unfolding. the how one a ex progress which against on platform, vivo, the third, some is It's we're quite a think first of it's the iPSC, those capital of The one just kind about

recapture ocular, as obviously so nice all a rights And we the that's for space.

smoothly. forward move to continues hopefully EDIT-XXX, As

that to And there go being focused think of a about cell them, whatever trial, iNK, that's is, a look to we're iPSC, to really When obviously, practice. the the there's cell differentiate future that at beta-thalassemia, the programs. same have on that You clone them, bit and and sickle particular you but we'd we're them, expand another be product. iNK starting able case, HSC quite relates the from on the or nice planning the opportunity platform platform. then reducing it'll edit with as different way And a actually you is successfully I In platform synergy them into this a like. type

addressing think with touched and which thinking on, Lisa we through edits we're I how there. will start

I So platform, it's that but not don't that's right. a yet, – is think settled not probably

think once edits, change edits technology, edits the to disease tumor we to about or segments a in think want add with Look, attentive different we're or continue the the around. to we delivery you few we start how advancement always address to that will. questions additional improve I different trying So can on Things platform we aspects. profiles, on fill of can the if of always to

deal. a do Beam saw You

plenty of was our we've off now, sort I to delivery. week, I earlier think right We this chew plate. not on on because probably think going got it are LMPs

So, would interesting big not us moment is at with been area probably for time. complex three very for have them the one manufacturing that in deal we this excited those about platforms. but Certainly,

within which some We as of – And the then outsourcing as activities LMPs ourselves that. with spaces. one in also activities have is well in of guides manufacturing of the Boulder, with their in-sourcing a some partnerships making or the we're performing couple for course, Catalent, the doing us really there, one controlled Azzur, the

specific some as those broadly. So more think you programs are these about of those

time, Now around and partnerships. partnerships business those we're to a I've long going this commercial been be need more manufacturing, academic, or partnerships, development whether

will be space. conversations. around really We time the different those question that And in engage the in timing active a programs. is It's for sure of best when to

to thinking progress to progress cell it's the need in for the that For the that And ocular programs medium near-term, of things iNK access the we the about. disease. and – progress have sickle matter the to long-term I'm like we to near-term, sort the

these And direction of so that. It's In how I'm the And business. it's just if products business but to – prospects will applications we broad and exciting circle you I'm to needs as very into platform these the practice. development company, platforms, the about only opens early thinking do successfully everybody technology. I this other three way broadly we clear the described probably can then product them each really science, to all it editing up not thinking need the which to do that one terms of we if for about days in gene I'm sort back, some dig the trying really world of very areas, speaking, have reduce but to partnerships, initial,

to you partners one them be just and your do make have who when to are. a about vaccine. Pfizer Even needed thoughtful You

have capabilities. open those you Hope expertise bringing answers question. So additional in in gaps just that filling the to to and and be very

Jay Olson

Thanks helpful. super the That’s for taking question.

Operator

Steve our with And from question last you. Seedhouse Thank is Raymond James.

Your question, please.

Ryan Deschner

you Steve spend is more on study time little with measurements? And Hi, that you'll taking other see barrel what Deschner do acuity in Thank at about review a be you XXXX? also, in how the statistically, a you. then bit this assessment gun points Could protocol visual R&D increasing talk for over Ryan data Seedhouse.

Lisa Michaels

All right.

first then So the second I'll one. one I'll the take off and hand

in CasX on period question six So come the Once primarily we week period visits that time very the for was have first in The easily to a potentially the is on were of the managed three time, damaging first where first the every actually past of we were not to actually some that potential four treated course, patients one, focusing for patients actually questions months. safety. some in or state. raised get routine apparatus of the of very key inflammatory that with result

the not bit what that in which study. I'm really allowed positive the a have that reminding enrolling we're type patients be be that, finding And us of of because in is to a folks huge seen is and their to patients more flexible light on the were of difference can discern the flashing safety and and eyes. first ability tell light whether low in that and to don't and also or the We with little only between has at consequence, just able me have actually for treated dose, vision. as a a who patients were They they concern, a front not two there's dark

whether much they can So actually or also routine patients, these of able not changes responses methods very not measurements. discern as the seeing to ability and measure we parts they shapes to to as whether well But as visual light concern see eye, different may anatomical through follow in light flashes changes can we're in of or be physiologic in physiologic walks also different pupil changes. the such sizes of those, measurements, mazes, whether or not to continuing through both the various be

and – through maze, I like, think all I got everything. So walking the sure I want to I make said

things three every to consistently are months that basically time, we continuing So moving the question? over Does measure these answer forward.

Ryan Deschner

you. Thank Yes.

Lisa Michaels

Okay.

So one. I'll second off the hand

Michelle Robertson

expense. so Yes, second I’ll the R&D handle one, the

those programs rights get back know, to responsible as ocular the that So program. we the fully you for we're

manufacturing. you'll cell, mentioned well So the in sickle investment, Jim obviously iNK as in continued as program particularly in see investment as ocular increased in

externally. investments manufacturing, we'll to So internally and both make in continue our significant

key in As regulatory well our positions clinical a hire as departments. continuing to operations and

Ryan Deschner

very you much. Thank Okay.

Operator

to for his this I And final remarks. to Q&A gentlemen, like you. would turn the our Mullen and ladies Thank session. concludes James call back

Jim Mullen

other questions, continuing look call goes progress for people talk this you morning, all on we data pretty and dialogue appreciate forward about clear the to clinical year are focused as you the to the the on. Thank and sitting on all what programs. through the And

Everyone it. you much. Thank weekend. have appreciate great So a very

Operator

disconnect. ladies participation, presentation. you again, gentlemen, your for and And you today's this concludes once Thank may now

Editas Medicine (EDIT) 25 Feb 212020 Q4 Earnings call transcript